

10th November, 2021

To

The Corporate Relations Department

BSE Limited

Phiroz Jeejeebhoy Towers, 25th Floor,

Dalal Street

Mumbai- 400001

Scrip Code - 543308

ISIN: INE967H01017

To

The Listing Department

National Stock Exchange of India Limited

Exchange Plaza,

Bandra Kurla Complex, Bandra (East)

Mumbai - 400 051

Symbol - KIMS

ISIN: INE967H01017

Dear Sir

Sub: Approval of unaudited Financial Results for the 2nd Quarter and Half year ended 30th September, 2021:

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have approved the unaudited Standalone and Consolidated Financial Results of the Company for the 2nd Quarter and Half year ended 30th September, 2021 at their meeting held on 10th November, 2021, which are enclosed herewith along with the Limited Review Reports issued by M/s. S.R. Batliboi & Associates LLP, the Statutory Auditors of the Company.

The financial results are also available on the website of the Company at www.kimshospitals.com and also on the websites of BSE Ltd and National Stock Exchange of India Ltd viz. www.bseindia.com and www.nseindia.com respectively.

The Board Meeting commenced at 4.00 PM and concluded at 6.40 Pm

This is for your information and records.

Thanking you,

For Krishna Institute of Medical Sciences Limited

Umashankar Mantha

Company Secretary & Compliance Officer

Encl : As above

Krishna Institute of Medical Sciences Limited

Minister Road, Secunderabad - 500 003, Telangana, India Phone: +91 40 4488 5000/4488 5184 | Fax: +91-40-27840980 | kimshospitals.com CIN: L55101TG1973PLC040558

Chartered Accountants

Oval Office, 18, iLabs Centre Hitech City, Madhapur Hyderabad - 500 081, India

Tel: +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Krishna Institute of Medical Sciences Limited

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Krishna Institute of Medical Sciences Limited (the "Company") for the quarter and six month period ended 30 September 2021 and year to date from 01 April 2021 to 30 September 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chartered Accountants

Other matters

5. The Statement includes the results for the corresponding quarter and six month period ended 30 September 2020 as reported in these Unaudited Financial Results have been prepared solely based on the information compiled by the management, and have not been subject to audit or review.

Our conclusion on the Statement is not modified in respect of this matter.

CHARTERED.

ACCOUNTANTS

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 21102328AAAAIA1212

Hyderabad

10 November 2021

Krishna Institute of Medical Sciences Limited
Corporate Identity number: U55101TG1973PLC040558
Registered office: 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Standalone Financial Results for the Quarter and Half year ended 30 September 2021

	(Rupe					Year ended		
			Quarter Ended			Half Year ended		
		30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	31-Mar-21	
		(Unaudited)	(Unaudited)	(Unaudited) Refer Note 2	(Unaudited)	(Unaudited) Refer Note 2	(Audited)	
1	Income						46.5 (2000)	
	(a) Revenue from operations	2,841.73	3,315.14	2,823.84	6,156.87	4,219.39	9,326.89	
	(b) Other income	93.38	40.17	18.71	133.55	56.82	96.15	
	Total Income	2,935.11	3,355.31	2,842.55	6,290.42	4,276.21	9,423.04	
2	Expenses					,		
	(a) Purchase of medical consumables, drugs and surgical	-						
	instruments	618.20	864.77	625.91	1,482.97	926.01	1,959.62	
	(b) Decrease / (increase) in inventories of medical consumables, drugs and surgical instruments	(14.59)	(55.88)	36.20	(70.47)	43.27	52.34	
	(c) Employee benefits expense	413.23	492.20	355.97	905.43	662.58	1,470.36	
	(d) Other expenses	844.03	903.09	734.13	1,747.12	1,178.15	2,804.28	
	(e) Finance cost	10.75	22.49	28.11	33.24	73.48	147.83	
	(f) Depreciation and amortisation expense	114.20	107.36	108.39	221.56	211.82	445.98	
	Total Expenses	1,985.82	2,334.03	1,888.71	4,319.85	3,095.31	6,880.41	
3	Profit before tax (1-2)	949.29	1,021.28	953.84	1,970.57	1,180.90	2,542.63	
4	Tax expense							
	(a) Current tax	243.71	263.54	253.35	507.25	308.89	668.12	
	(b) Deferred tax credit	(7.48)	(3.88)	0.89	(11.36)	2.49	(1.64)	
	(c) Adjustment of tax relating to earlier periods	-	-	(10.34)	-	(10.34)	(10.34	
	Total tax expenses	236.23	259.66	243.90	495.89	301.04	656.14	
5	Profit for the period/year (3-4)	713.06	761.62	709.94	1,474.68	879.86	1,886.49	
6	Other comprehensive income							
	Items that will not be reclassified subsequently to statement of profit and loss							
	- Re-measurement loss on defined benefit plans	(7.51)	(1.60)	(0.18)	(9.11)	(3.20)	(6.40	
	- Income tax effect	1.89	0.40	0.05	2.29	0.81	1.61	
	Other comprehensive income, net of tax	(5.62)	(1.20)	(0.13)	(6.82)	(2.39)	(4.79	
			\					
7	Total comprehensive income (5+6)	707.44	760.42	709.81	1,467.86	877.47	1,881.70	
0	Paid up equity share capital (face value of Rs.10 each)						775.93	
8	Other Equity			9			8,297.30	
	Earnings per share (of Rs.10 each): (not annualised for the						6,297.30	
10	quarter ended)			9				
	(a) Basic (Rs.)	8.91	9.81	9.53	19.63	11.81	25.20	
	(a) Basic (Rs.) (b) Diluted (Rs.)	8.91	9.81	9.33	19.63	11.72	23.20	
	(U) Diluted (NS.)	8.91	9.81	9.46	19.03	11.72	24.77	





Notes:

- In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Standalone Financial Results for the quarter and half year ended 30 September 2021 ("Unaudited Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 November 2021 and have been subject to a limited review by the statutory auditors of the Company. An unqualified report was issued by them theron.
- The Unaudited Standalone financial results for the corresponding quarter and half year ended 30 September 2020, have not been subject to an audit or review by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the Unaudited Standalone financial results for these periods provide a true and fair view of the Company's affairs.
- The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- The Unaudited Standalone Balance sheet and Unaudited Standalone Statement of Cash Flows are set out in Annexure I and Annexure II respectively.
- 5 The Company has completed Initial Public Offer ("IPO") of 25,995,042 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 825/- per Equity Share, comprising offer for sale of 23,560,538 shares by Selling Shareholders and fresh issue of 2,434,504 shares. The Equity Shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 28 June 2021.

The utilisation of the net IPO proceeds is summarised below

Particulars	Objects of the issue as per prospectus *	Utilisation upto 30 September 2021	Unutilised amount as on 30 September 2021
Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and by our Subsidiaries	1,500.00	1,500.00	
General Corporate Purpose	416.60	416.60	-
Total	1,916,60	1.916.60	-

* net of Offer expenses to the extent applicable to the Fresh Issue

- The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 8 The Company operates in one single reportable business segment- "Medical and Healthcare services"
- ⁹ The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of it's business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.
- Subsequent to 30 September 2021, the Company has entered into a share purchase agreement ('SPA') and shareholders agreement ('SHA') dated 27 October 2021, with the existing promoter and certain other shareholders of Sarvejana Healthcare Private Limited ('Sunshine Hospitals') to acquire 51.07% of the equity share capital of the Sunshine Hospitals (as a combination of 17.6% stake through equity shares and the remainder through partly paid up equity shares, which shall be fully paid up by April 2022 based on agreed schedule). The Sunshine Hospitals is engaged in the healthcare industry. The said acquisition is subject to the fulfillment of various terms and conditions as specified in the SPA and SHA.
- 11 The previous periods numbers have been regrouped/rearranged wherever necessary to conform the current period presentation.
- The above Unaudited Standalone Financial Results of the Company are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board

Krishna Institute of Medical Sciences Limited

Hyderabad

10 November 2021

Dr. B Bhaskara Rao Managing Director DIN: 00008985





Krishna Institute of Medical Sciences Limited
Corporate Identity number: U55101TG1973PLC040558
Registered office: 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS@kimshospitals.com, Tel: 040 7122 5000

Unaudited Standalone Balance Sheet as at 30 September 2021

	(Rupees in millions)			
	As at	As at		
Particulars	30 September 2021	31 March 2021		
	(Unaudited)	(Audited)		
A ASSETS				
1 Non current Assets				
Property, plant and equipment	5,747.59	5,771.77		
Capital work-in-progress	70.98	76.03		
Intangible assets	123.96	-31.30		
Right-of-use assets	3.05	20.7		
Financial assets				
(i) Investments	2,143.53	2,132.2		
(ii) Loans	1,143.35	190.6		
(iii) Other financial assets	157.01	107.9		
Non-current tax assets (net)	22.84	40.3		
Other non-current assets	110.04	93.9		
Total Non current Assets - (1)	9,522.35	8,465.0		
2 Current Assets				
Inventories	235.20	164.7		
Financial assets				
(i) Trade receivables	784.77	730.04		
(ii) Cash and cash equivalents	362.26	345.8		
(iii) Bank balances other than (ii) above	3,451.11	2,154.3		
(iv) Loans	84.98	6.40		
(v) Other financial assets	368.18	224.2		
Other current assets	113.56	46.6		
Total Current Assets - (2)	5,400.06	3,672.25		
3 Total Assets (3) = (1)+(2)	14,922,41	12,137.2		
4 Equity and Liabilities	14,722.41	12,10712		
Equity share capital	800.28	775.93		
Other equity	11,670.08	8,297.30		
Total Equity - (4)	12,470.36	9,073.2		
B LIABILITIES	12,470.50	7,075,2.		
5 Non-current liabilities				
Financial liabilities				
(i) Borrowings	112.91	677.84		
(ii) Lease liabilities	1.66	18.89		
(iii) Other financial liabilities	0.09	0.0		
Provisions	126.87	142.4		
Other non-current liabilities	1.63	22.73		
Deferred tax liabilities (net)	287.48	301.14		
Total Non-current liabilities - (5)	530.64	1,163.1		
6 Current liabilities	330.04	1,103.1.		
Financial liabilities				
	142.32	609.8		
(i) Borrowings	3.33	6.7		
(ii) Lease liabilities	3.33	0.7.		
(iii) Trade payables				
(a) Total outstanding dues of micro enterprises and small	0.75	2.5		
enterprises; and	0.75	2.5		
(b) Total outstanding dues of creditors other than micro	007.50	0.40.2		
enterprises and small enterprises	996.59	849.3		
(iv) Other financial liabilities	236.51	97.2		
Provisions	81.87	76.4		
Other current liabilities	309.91	195.3		
Current tax liabilities (Net)	150.13	63.4		
Non-current liabilities - (6)	1,921.41	1,900.8		
Total Equity and Liabilities (7) = (4)+(5)+(6)	14,922.41	12,137.2		





Krishna Institute of Medical Sciences Limited
Corporate Identity number: U55101TG1973PL.C040558
Registered office: 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email. CS@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Standalone Cashflows for the Half Year Ended 30 September 2021

	For the half year	For the half year
	ended	ended
Particulars	30-Sep-21	30-Sep-20
.A	(Unaudited)	(Unaudited) Refer Note 2
1. Cash flows from operating activities:		
Profit before tax for the period/year	1,970.57	1,180.90
Adjustments for operating activities:		
Depreciation and amortisation expenses	221.56	211.82
Loss on sale of property, plant and equipment	26.30	0.50
Expected credit loss for trade receivables	41.36	9.52
Trade receivables written off	2.08	-
Investment written off	(24.42)	(7.00
Guarantee commission income	(24.43)	(0.61
Rental income	(0.69)	(0.01
Profit on termination of lease	(2.57)	-
Interest income on fixed deposits, security deposit and loan to	(98.27)	(15.93
related parties		(0.27
Liabilities no longer required written back Interest income on income tax refund	-	(8.27
Finance cost	33.24	73.48
Operating cash flows before working capital changes	2,169.15	1,443.64
Adjustments for:		
Decrease /(increase)	(98.17)	356.18
in trade receivables	(70.47)	43.28
in inventories	(174.68)	(136.28
in loans, Other financials assets and other assets	(174.08)	(130.20
Increase in trade payables, other financial liabilities, provisions	429.06	85.87
and other liabilities	2,254,89	1,792.69
Cash generated from operations Income taxes paid, net of refunds	(424.31)	(47.54
Net cash generated from operating activities (1)	1,830.58	1,745.15
II. Cash flows from investing activities		
Purchase of property, plant and equipment and intangible assets	(342.95)	(127.76
Proceeds from sale of property, plant and equipment	2.36	2.13
Investment in subsidiaries	(11.30)	(67.50
Loans given to subsidiaries	(1,156.33)	(150.00
Receipt of loans given to subsidiaries	125.00	45.00
Redemption of bank deposits (having original maturity of more	1 721 01	22.27
than three months)	1,731.01	22.26
Investment in bank deposits (having original maturity of more	(2.075.71)	(4.07
than three months)	(3,075.71)	(4.07
Lease income received	0.69	0.61
Interest received	(2,662.67)	19.63 (259.70
Net cash used in investing activities (2)	(2,002.07)	(239.70
III. Cash flows from financing activities		
Repayment of long-term borrowings	(532.48)	(775.18
Proceeds / (repayment) of short-term borrowings (net)	(500.00)	(20.81
Payment of lease obligations	(5.12)	(7.12
Proceeds from issue of shares	1,916.60	-
nterest paid	(30.50)	(74.33
Net cash flows generated from / (used in) financing activities (3	848.50	(877.44
Net increase in cash and cash equivalents (1+2+3)	16.41	608.01
Cash and cash equivalents at the beginning of the year	345.85	344.70
Cash and cash equivalents at the end of the period/year	362.26	952.71
Components of cash and cash equivalents		
Cash on hand	14.65	30.38
Balances with banks		
- On current accounts	347.61	326.08
- In deposit accounts	-	596.25
Total Total	362.26	952.71





Chartered Accountants

Oval Office, 18, iLabs Centre Hitech City, Madhapur Hyderabad - 500 081, India

Tel: +91 40 6141 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Krishna Institute of Medical Sciences Limited

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter and six month period ended 30 September 2021 and year to date from 01 April 2021 to 30 September 2021 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.no.	Entity	Polational:
1	Krishna Institute of Medical Sciences Limited	Relationship
2	Arunodaya Hospitals Private Limited	Holding Company
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Modical Colonics Private Limited	Subsidiary
6	Saveera Institute of Medical Sciences Private Limited	Subsidiary
7	KIMS Hospital Kurnool Private Limited	Subsidiary
8	KIMS Hospitals Private Limited	Subsidiary
9	KIMS Swastha Private Limited	Subsidiary
	KIMS Cuddles Private Limited*	Subsidiary
210	KIMS Hospital (Bhubaneswar) Private Limited	Subsidiary

ubsidiary has filed necessary closure forms for strike off with RoC on February 9, 2021

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matters

- 6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of:
 - Four subsidiaries, whose unaudited interim financial results include total revenues of Rs Nil, total net loss after tax of Rs. 0.87 million and 1.73 million, total comprehensive loss of Rs. 0.87 million and 1.73 million for the quarter and six month period ended 30 September 2021 respectively, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

7. The Statement includes the results for the corresponding quarter and six month period ended 30 September 2020 as reported in these Unaudited Financial Results have been prepared solely based on the information compiled by the management, and have not been subject to audit or review.

Our conclusion on the Statement is not modified in respect of this matter.

CHARTERED

ACCOUNTANTS

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 21102328AAAAHZ5456

Place: Hyderabad

Date: 10 November 2021

Krishna Institute of Medical Sciences Limited
Corporate Identity number: U55101TG1973PLC040558
Registered office: 1-8₅31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS a kimshospitals.com, Tel: 040-7122-5000

Statement of Unaudited Consolidated Financial Results for the Quarter and Half year ended 30 September 2021

	r					Year ended	
			Quarter Ended	20.6 20		30-Sep-20	31-Mar-21
		30-Sep-21 (Unaudited)	30-Jun-21 (Unaudited)	30-Sep-20 (Unaudited) Refer Note 2	30-Sep-21 (Unaudited)	(Unaudited) Refer Note 2	(Audited)
1	Income			In house of large			
	(a) Revenue from operations	4,117.40	4,731.79	4,096.33	8,849.19	6,107.34	13,299.3
	(b) Other income	54.06	42.73	15.24	96.79	58.93	101.6
	Total Income	4,171.46	4,774.52	4,111.57	8,945.98	6,166.27	13,401.0
2	Expenses	873.95	1,193.02	926.74	2,066.97	1,352.25	2,826.3
	(a) Purchase of medical consumables, drugs and surgical instruments	873.93	1,193.02	920.74	2,000.97	1,332.23	2,020.3
	(b) Decrease / (increase) in inventories of medical consumables, drugs and surgical instruments	(18.79)	(69.60)	37.40	(88.39)	41.61	62.5
	(c) Employee benefits expense	635.04	725.13	551.75	1,360.17	1,018.79	2,202.0
	(d) Other expenses	1,339.41	1,446.56	1,167.88	2,785.97	1,924.96	4,499.1
	(e) Finance cost	28.87	63.22	68.99	92.09	160.37	324.9
	(f) Depreciation and amortisation expense	181.40	170.88	164.10	352.28	333.52	695.3
	Total Expenses	3,039.88	3,529.21	2,916.86	6,569.09	4,831.50	10,610.8
3	Profit before tax (1-2)	1,131.58	1,245.31	1,194.71	2,376.89	1,334.77	2,790.1
4	Tax expense						
	(a) Current tax	299.66	338.07	308.49	637.73	368.39	778.3
	(b) Deferred tax credit	(10.62)	(13.06)	(5.33)	(23.68)	(14.41)	(33.0
	(c) Adjustment of tax relating to earlier periods	()		(10.00)		(10.00)	(10.0
	Total tax expenses (4)	289.04	325.01	293.16	614.05	343.98	735.3
5	Profit for the period/year (3-4)	842.54	920,30	901.55	1,762.84	990.79	2,054.7
	Attributable to:						
	Owners of the company	817.17	891.05	834.75	1,708,22	946.26	2,012.
	Non controlling interests	25.37	29.25	66.80	54.62	44.53	42.0
6	Other comprehensive income						
	Items that will not be reclassified subsequently to statement of profit and loss						
	- Re-measurement loss on defined benefit plans	(10.44)	(1.47)	0.02	(11.91)	(3.14)	(6.2
	- Income tax effect	2.68	0.38	-	3.06	0.80	1.0
	Other comprehensive income, net of tax	(7.76)	(1.09)	0.02	(8.85)	(2.34)	(4.0
	Other comprehensive income/(Loss) for the period/year:						
	Attributable to:						
	Owners of the company	(6.99)	(1.19)	(0.15)	(8.18)	(2.47)	(4.9
	Non controlling interests	(0.77)	0.10	0.16	(0.67)	0.12	0.3
	Other comprehensive income/(Loss)	(7.76)	(1.09)	0.01	(8.85)	(2.35)	(4.
7	Total comprehensive income (5+6)						
ď -	Owners of the company	806,73	889.58	834.77	1,696.31	943.12	2,005.
	Non controlling interests	28.05	29.63	66.80	57.68	45.33	44.
	Total comprehensive income	834.78	919.21	901.57	1,753.99	988.45	2,050.
8	Paid up equity share capital (face value of Rs.10 each)						775.
9	Other Equity			- 1			7,861.
.5	Earnings per share (of Rs.10 each): (not annualised)						.,,,,,,,
10	(a) Basic (Rs.)	10,34	11.48	11.21	22.87	12.71	26.
	(b) Diluted (Rs.)	10.34	11.48	11.12	22.87	12.61	26.





Notes

- In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the Half year ended 30 Sep 2021 ("Unaudited Consolidated Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 November 2021 and have been subject to a
- limited review by the statutory auditors of the Company. An unqualified report was issued by them theron.
 The Unaudited Consolidated financial results for the corresponding quarter and half year ended 30 September 2020, have not been subject to an audit or review by our statutory auditors. However, the
- management has exercised necessary due diligence to ensure that the Unaudited Consolidated financial results for these periods provide a true and fair view of the Group's affairs.

 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- The Unaudited Consolidated Balance sheet and Unaudited Consolidated Statement of Cash Flows are set out in Annexure I and Annexure II respectively
- The Company has completed Initial Public Offer ("IPO") of 25,995,042 Equity Shares of the face value of Rs. 10½ cach at an issue price of Rs. 8,25½ per Equity Share, comprising offer for sale of 23,560,538 shares by Selling Shareholders and fresh issue of 2,434,504 shares. The Equity Shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 28 June 2021.
- The utilisation of the net IPO proceeds is summarised below

Particulars	Commence and the commence of t	Utilisation upto 30 September 2021	Unutilised amount as on 30 September 2021
Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and by our Subsidiaries	1,500.00	1,500.00	-
General Corporate Purpose	416.60	416.60	-
Total	1,916.60	1,916.60	-

- *not of Officr expenses to the extent applicable to the Fresh Issue.

 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Company is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- The Company operates in one single reportable business segment- "Medical and Healthcare services".
- The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Company is closely monitoring the impact of the pandemic on all aspects of it's business, including how it will impact its employees, vendors and business partners. The Company based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact. Based on the current estimates, the Company expects to fully recover the carrying amount of assets, and does not foresee
- any material adverse impact on its operations. As the outbreak continues to evolve, the Company will continue to closely monitor any material changes to future economic condition.

 Subsequent to 30 September 2021, the Company has entered into a share purchase agreement ('SPA') and shareholders agreement ('SPA') dated 27 October 2021, with the existing promoter and certain other shareholders of Sarvejana Healthcare Private Limited ('Sunshine Hospitals') to acquire 51.07% of the equity share capital of the Sunshine Hospitals (as a combination of 17.6% stake through equity shares and the remainder through partly paid up equity shares, which shall be fully paid up by April 2022 based on agreed schedule). The Sunshine Hospitals is engaged in the healthcare industry. The said acquisition is subject to the fulfillment of various terms and conditions as specified in the SPA and SHA.
- The previous periods numbers have been regrouped/rearranged wherever necessary to conform the current period presentation
- The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed

For and on behalf of the Board

Krishna Institute of Medical Sciences Limited

Dr. B Bhaskara Rac Managing Director DIN: 00008985

Hyderabad 10 November 2021



Secunderabad m

OF ME

Annexure - I

Krishna Institute of Medical Sciences Limited
Corporate Identity number: US\$101TG1973PLC040558
Registered office: 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS a kimshospitals.com, Tel: 040 7122 5000

Unaudited Consolidated Balance Sheet as at 30 September 2021

	\$ \$1.00 \$1.0	As at	As at
S.No	D		31 March 202
5.110	Particulars	30 September 2021	
-	LCCCTC	(Unaudited)	(Audited)
A	ASSETS	-	
1	Non current Assets	7.402.41	7.704
	Property, plant and equipment	7,682.61	7,706
	Capital work-in-progress	97.96	92
	Goodwill	847.75	847
	Other Intangible assets	334.70	247
	Right-of-use assets	468.51	509
	Financial assets		
	(i) Other financial assets	419.10	192
	Deferred tax asset (net)	22.66	25
	Non-current tax assets (net)	114.40	103
	Other non-current assets	404.19	121
	Total Non current Assets - (1)	10,391.88	9,849
2	Current Assets		
	Inventories	329.24	240
	Financial assets		
	(i) Trade receivables	1,205.34	1,098
	(ii) Cash and cash equivalents	454.05	52
	(iii) Bank balances other than (ii) above	3,497.11	2,323
	(iv) Other financial assets	397.76	257
	Other current assets	150.67	70
	Total Current Assets - (2)	6,034.17	4,511
	Total Assets $(3) = (1)+(2)$	16,426.05	14,361
В	LIABILITIES		
4	EQUITY AND LIABILITY		
	Equity share capital	800.28	. 775
- 1	Other equity	11,456.72	7,861
	Equity attributable to Shareholders of the company - (4)	12,257.00	8,637
	Non-controlling interests - (5)	176.91	124
	Total Equity (6) = $(4)+(5)$	12,433.91	8,761
	Non-current liabilities		
	Financial liabilities		
- 1	(i) Borrowings	264.96	1.840
- 1	(ii) Lease liabilities	404.29	433
	(iii) Other financial liabilities	4.85	
	Provisions	148.42	160
- 1	Other non-current liabilities		12
- 1	Deferred tax liabilities (net)	336.20	358
	Total Non-current liabilities - (7)	1,158.72	2,816
	Current liabilities	1,100172	2,010
	Financial liabilities	-	
	(i) Borrowings	235.10	858
	(ii) Lease liabilities	25.66	25
- 1	(iii) Trade payables	25.00	23
- 1	(a) Total outstanding dues of micro enterprises and small enterprises; and	45,62	17
	(b) Total outstanding dues of mero enterprises and small enterprises; and	43.02	17
	cnterprises	1.527.23	1,300
	(iv) Other financial liabilities	351.58	161
	Provisions Other and Michigan	122.35	104
- 1	Other current liabilities	355.48	227 87
- 1:			
	Current tax liabilities (Net) Fotal Non-current liabilities - (8)	170.40 2,833.42	2,783





Annexure - II

Krishna Institute of Medical Sciences Limited
Corporate Identity number: U55101TG1973PLC040558
Registered office: 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: CS a kimshospitals.com, Tel: 040-7122-5000

Statement of Unaudited Consolidated Cashflows for the Half Year Ended 30 September 2021

Cash flows from operating activities: Profit before tax for the periodycar 2,376,89 1,335,0 Adjustments for operating activities: Depreciation and amortisation expenses 352,28 333,35,0 Depreciation and amortisation expenses 352,28 333,35,0 Expected credit loss for trade receivables 79,73 22,2 Expected credit loss for trade receivables 79,73 22,2 Trade receivables written off 9,94 0.7 Rental income (5,70) (5,70) Profit on termination of lease (22,57) Interest income on fixed deposits and security deposit (22,94 (20,1) Liabilities no longer required written back (38,2) (30,2) Finance cost (32,20) (160,3) Departing cash flows before working capital changes (22,50,33 1,802,6 Adjustments for: (38,39) (41,6) Departing cash flows before working capital changes (38,39) (41,6) Departing cash flows before working capital changes (38,39) (41,6) Departing cash flows before working capital changes (38,39) (41,6) Departing cash flows before working capital changes (38,39) (41,6) Departing cash flows before working capital changes (38,39) (41,6) Departing cash flows before working capital changes (38,39) (41,6) Departing cash flows before working capital changes (38,39) (41,6) Departing cash flows assets (46,49) (22,49) Departing cash flows assets (46,49) (22,49) Departing cash flows assets (46,49) (22,49) Departing cash flows assets (46,49) (23,49) Cash generated from operations (46,49) (23,49) Cash generated from operations (46,49) (23,49) Cash generated from operating activities (11,41) (67,54) Departing cash flows from investing activities (11,41) (67,54) (48,49) (49,67,3)		For the half year	For the half year
Cash flows from operating activities: Profit before tax for the periody-car Adjustments for operating activities: Profit before tax for the periody-car Adjustments for operating activities: Depreciation and amortisation expenses S25,28 333,50 Adjustments for operating activities: Depreciation and amortisation expenses 352,28 333,50 Expected credit loss for trade receivables 79,73 22,2 Profit Jo. See and see of property, plant and equipment 26,43 (0.7 Rental income 5,70 9,94 0.7 Rental income 5,70 9,94 0.7 Rental income 7,294 (2.01 Itabilities no longer required written back (2.257) Itabilities no longer required written back (38,2) (30,2) Primarce cost 22,09 160,3 Departing cash flows before working capital changes 2,850,33 1,802,6 Adjustments for: Decrease / Ifinerase) (196,82) 390,9 Introder receivables (196,82) 39		ended	ended
Cash flows from operating activities: Profit before tax for the period/year 2,376,89 1,335,00 Adjustments for operating activities: 2,376,89 1,335,00 Depreciation and amortisation expenses 352,28 333,5 Profit/Loss on sale of property, plant and equipment 26,43 (0.77 2.72 2.72 2.73 2.74 2.	Particulars	30-Sep-21	30-Sep-20
Profit before tax for the period/year		(Unaudited)	(Unaudited) Refe Note 2
Adjustments for operating activities: Depreciation and amortisation expenses Depreciation and amortisation expenses Depreciation and amortisation expenses 26.43 (0.77) 22.24 (0.77) 27.3 (0.72) 22.25 (0.77) 23.22 (0.77) 24.25 (0.77) 25.	I. Cash flows from operating activities:	N	NAMES AND ADDRESS OF THE PARTY
Depreciation and amortisation expenses 33.2.28 33.3.5	Profit before tax for the period/year	2,376.89	1,335.01
Profity/Loss on sale of property, plant and equipment		0000000000	100000000000000000000000000000000000000
Expected credit loss for trade receivables 79,73 2, 2.2 Trade receivables written off 99.4 0.7 Rental income (5.70) (3.3 Profit on termination of lease (2.57) Interest income on fixed deposits and security deposit (2.294) (20.1 Liabilities no longer required written back (5.82) (5.9) 1603 Diperating cash flows before working capital changes 2,850,33 1,802,6 Adjustments for: Decrease / (increase)			
Trade receivables written off 9.94 0.7			
Rental income Profit on termination of lease Profit on the profit of lease Profit of lease Profit of lease Profit on the profit of lease Profit of lea			
Profit on termination of lease Interest income on fixed deposits and security deposit Interest income on fixed deposits and security deposit Interest income on fixed deposits and security deposit Intabilities no longer required written back Introduced Introdu		1000000	
Interest income on fixed deposits and security deposit			
Cash	Profit on termination of lease		
Finance cost Operating cash flows before working capital changes Adjustments for: Decrease (finerease) in inventories in intrade receivables in inventories (651.63) (221.9 increase/(decrease) in trade payables, other financial liabilities, provisions and other liabilities Cash generated from operations income taxes paid, net of refunds (553.73) (47.3 (47.3) (47.3) (48.2) (49.8) (40.49) (237.3) (47.4) (48.2) (49.49) (237.3) (47.4) (48.2) (49.49) (48.32.09) (48.30) (4	Interest income on fixed deposits and security deposit		
Adjustments for:	Liabilities no longer required written back		
Adjustments for: Decrease //increase) - in trade receivables - in interactories - in interactories - in interactories - in interactories - in interaction financials assets and other assets - in other financials assets and other assets - in content financial assets and other assets - in interaction operations - (651,63) - (221,9 - (261,63) - (221,9 - (261,63) - (221,9 - (261,63) - (219,68) - (219,58) - (20,58) - (Finance cost		
Decrease / finerease) (196,82) 390.9 in trade receivables (88,39) 41.6 in the financials assets and other assets (681,63) (221.9 in Chefr financial sasets and other assets (651,63) (221.9 in Crease/(decrease) in trade payables, other financial liabilities, provisions and other liabilities 596,09 61.7 Cash generated from operations 2,509,58 2,075.0 income taxes paid, net of refunds (533,73) (47.3 Net cash generated from operating activities (1) 1,955,88 2,027.7 II. Cash flows from investing activities (462.49) (237.3 Proceeds from sale of property, plant and equipment 2,45 2,1 investment in subsidiaries (11.31) (67.5 Redemption of bank deposits (having original maturity of more than three months) 3,620.10 23.3 investment in bank deposits (having original maturity of more than three months) (4,832.09) (143.0 increase income received 5,70 3.3 3.0 increase income received 54.9 19.9 interest received 54.9 19.9 <td>Operating cash flows before working capital changes</td> <td>2,850.33</td> <td>1,802.65</td>	Operating cash flows before working capital changes	2,850.33	1,802.65
in trade receivables (196.82) 390.9 in inventories (88.39) 41.6 (651.63) (221.9 (651.63) (235.373) (47.3	Adjustments for:		
in inventories in inv	Decrease /(increase)		
in Other financials assets and other assets increase/(decrease) in trade payables, other financial liabilities, provisions and other liabilities	- in trade receivables		
Increase			
Cash generated from operations 2,509.58 2,075.0		(651.63)	(221.90
1. Cash flows from investing activities (237.3 (47.3 (237.	Increase/(decrease) in trade payables, other financial liabilities, provisions and other liabilities	596.09	61.77
Net cash generated from operating activities (1) 1. Cash flows from investing activities Purchase of property, plant and equipment and intangible assets Proceeds from sale of property, plant and equipment (462.49) (237.3 Proceeds from sale of property, plant and equipment (11.31) (67.5 Redemption of bank deposits (having original maturity of more than three months) (4,832.09) (13.0) (13.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (14.0) (15.0) (15.0) (16.0) (17.12.86) (17.	Cash generated from operations	2,509.58	2,075.06
Cash flows from investing activities Capture Captu	Income taxes paid, net of refunds	(553.73)	(47.30
Purchase of property, plant and equipment and intangible assets	Net cash generated from operating activities (1)	1,955.85	2,027.77
Proceeds from sale of property, plant and equipment	II. Cash flows from investing activities		
investment in subsidiaries (11.31) (67.5 Redemption of bank deposits (having original maturity of more than three months) (4,832.09) (143.0 .ease income received (5.70) (143.0 .ease income received (5.4.9) (19.0 .ease income received (1.623.15) (399.0 .ease income of long-term borrowings (1.72.86) (850.1 .ease and long-term borrowings (1.72.86) (850.1 .ease and lease obligations (30.19) (17.9 .ease and lease obligations (30.19) (17.9 .ease and cash obligations (1.624.0 .ease and long-term borrowings (net) (1.624.0 .ease and lease of shares (1.916.60 .ease and lease of shares (1.916.60 .ease and lease and cash equivalents (1+2+3) (399.93) (993.5 .ease and lease and cash equivalents (1+2+3) (399.93) (993.5 .ease and lease and cash equivalents at the beginning of the year (5.12.9 .ease and lease and cash equivalents at the end of the period/year (454.06 .ease and lease and lease equivalents (1.640.2 .ease and lease equivalents at the end of the period/year (454.06 .ease and lease equivalents at the end of the period/year (454.06 .ease and lease equivalents (1.62.1 .ease and lease equivalents	Purchase of property, plant and equipment and intangible assets	(462.49)	(237.38
Redemption of bank deposits (having original maturity of more than three months) 7, 3, 20, 10 7, 3, 3, 3, 3, 10, 10 7, 10, 23, 3, 10, 10 7, 10, 23, 3, 10, 10 7, 10, 23, 3, 10, 10 7, 10, 23, 3, 10 7, 10, 23, 3, 10 7, 10, 23, 3, 10 7, 10, 23, 3, 10 7, 10, 23, 3, 10 7, 10, 23, 3, 10 7, 10, 23, 3, 10 7, 10, 23, 15 7, 23, 15 7, 24, 25 7	Proceeds from sale of property, plant and equipment	2.45	2.12
Avestment in bank deposits (having original maturity of more than three months) (4,832.09) (143.0 (5,70) (3.3 (5,70) (3.4) (1,623.15) (3.99.0 (1,623.15) (1,623.15) (3.99.0 (1,623.15) (1,623.15) (3.99.0 (1,623.15) (1,623.15) (3.99.0 (1,72.86) (1,712.86) (850.1 (1,72.86) (1,72.86)	Investment in subsidiaries	(11.31)	(67.50
Lease income received 5.70 3.3 anterest received 5.4,9 19.9 service as the used in investing activities (2) (1,623.15) (399.0 ll. (1	Redemption of bank deposits (having original maturity of more than three months)	3,620.10	23.37
Lease income received 5,70 3,3 Anterest received 5,40 19,9 Net cash used in investing activities (2) (1,623.15) (399.0) III. Cash flows from financing activities Repayment of long-term borrowings (1,712.86) (850.1 Proceeds from long-term borrowings (1,712.86) (850.1 Proceeds from long-term borrowings (496.73) 9.3 Ayment of lease obligations (30.19) (17.9 Proceeds from issue of shares 1,916.60 Proceeds from issue of shares 1,916.60 Ret cash flows generated from / (used in) financing activities (3) (399.93) (993.5 Net increase in cash and cash equivalents (1+2+3) (67.23) (351.1 Lash and cash equivalents at the beginning of the year 521.29 405.1 Cash and cash equivalents at the end of the period/year 454.06 1,040.2 Components of cash and cash equivalents 19.48 35.9 Balances with banks 19.48 35.9 Balances with banks 434.58 448.1 In deposit accounts (with original maturity of 3 months or less) 596.2 Cash or land 19.48 434.58 448.1 Cash or land 19.48 434.58 448.1 Cash or land 19.48 434.58 448.1 Cash original maturity of 3 months or less 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 Cash countries accounts (with original maturity of 3 months or less) 596.2 C	Investment in bank deposits (having original maturity of more than three months)	(4,832.09)	(143.01
Net cash used in investing activities (2) III. Cash flows from financing activities Repsyment of long-term borrowings (net) Repsyment of lease obligations Repsyment of	Lease income received	5.70	3.37
Net cash used in investing activities (2) III. Cash flows from financing activities Repayment of long-term borrowings Repayment of lease obligations Repayment of lease ob	Interest received	54.49	19.93
Repayment of long-term borrowings	Net cash used in investing activities (2)	(1,623.15)	(399.09
Proceeds from long-term borrowings Proceeds / (repayment) of short-term borrowings (net) Proceeds from issue of shares Proceeds from issue objection Proceeds from issue objec	III. Cash flows from financing activities		
Proceeds / (repayment) of short-term borrowings (net) (496,73) 9,3 'ayment of lease obligations (30,19) (17,9) 'receeds from issue of shares 1,916,60 'nterest paid (76,74) (134,8 'Net cash flows generated from / (used in) financing activities (3) (399,93) (993,5) 'Ret increase in cash and cash equivalents (1+2+3) (67,23) (351,1) 'Cash and cash equivalents at the beginning of the year 521,29 405,1- 'Cash and cash equivalents at the end of the period/year 454,06 1,040,2 'Components of cash and cash equivalents 'Cash on hand 19,48 35,9 Balances with banks 434,58 408,11 - On current accounts - In deposit accounts (with original maturity of 3 months or less) - 566,2	Repayment of long-term borrowings	(1,712.86)	(850.10
Payment of lease obligations (30.19) (17.9) Proceeds from issue of shares (1,916.60) Interest paid (76.74) (134.8) Vet cash flows generated from / (used in) financing activities (3) (399.93) (993.5) Net increase in cash and cash equivalents (1+2+3) (67.23) (635.1) Tash and cash equivalents at the beginning of the year (21.29) 405.1 Tash and cash equivalents at the end of the period/year (454.06) (1,040.2) Tash on hand (19.8) (19.8) (19.8) Tash on hand (19.8) (19.8) (19.8) Tash on hand (19.8) (19.8) (19.8) (19.8) Tash on courted accounts (19.8) (19.	Proceeds from long-term borrowings	-	
Proceeds from issue of shares 1,916.60 (134.8 (134.8 (16.74) (134.8 (134.8 (16.74) (134.8 (134.8 (16.74) (134.8 (134.8 (16.74) (134.8 (134.8 (16.74) (134.8 (134.8 (16.74) (134.8 (134.8 (16.74) (134.8 (134.	Proceeds / (repayment) of short-term borrowings (net)	(496.73)	9.32
13.4.8 1	Payment of lease obligations	(30.19)	(17.93
Net cash flows generated from / (used in) financing activities (3) (399.93) (993.5) Net increase in cash and cash equivalents (1+2+3) (67.23) (65.1) Cash and cash equivalents at the beginning of the year 521.29 405.1 Cash and cash equivalents at the end of the period/year 454.06 1,040.2 Components of cash and cash equivalents Cash on hand 19.48 35.9 Balances with banks On current accounts - 1434.58 408.11 In deposit accounts (with original maturity of 3 months or less) - 596.2	Proceeds from issue of shares	1,916.60	-
Net increase in cash and cash equivalents (1+2+3) (67.23) 635.1. 2ash and cash equivalents at the beginning of the year 521.29 405.1. Cash and cash equivalents at the end of the period/year 454.06 1,040.2. Components of cash and cash equivalents 2ash on hand 19.48 33.9. Balances with banks - On current accounts - In deposit accounts (with original maturity of 3 months or less) - 596.2.	Interest paid	(76.74)	(134.84
Cash and cash equivalents at the beginning of the year 521.29 405.1	Net cash flows generated from / (used in) financing activities (3)	(399.93)	(993.55
Cash and cash equivalents at the beginning of the year 521,29 405.1 Cash and cash equivalents at the end of the period/year 454.06 1,040.2 Components of cash and cash equivalents 19.48 35.9 Salances with banks - - - - On current accounts 434.58 408.1 - In deposit accounts (with original maturity of 3 months or less) - 596.2	Net increase in cash and cash equivalents (1+2+3)	(67.23)	635.12
Cash and cash equivalents at the end of the period/year 454,06 1,040.2 Components of cash and cash equivalents 19.48 35.9 2ash on hand 19.48 35.9 3alances with banks 434.58 408.11 - On current accounts 43.58 408.11 - In deposit accounts (with original maturity of 3 months or less) - 596.2		521.29	405.14
Components of cash and cash equivalents 19.48 35.9 2ash on hand 19.48 35.9 2alances with banks - - - On current accounts 434.58 408.19 - In deposit accounts (with original maturity of 3 months or less) - 596.2		454.06	1,040.26
Salances with banks 434.58 408.19 - In deposit accounts (with original maturity of 3 months or less) 596.2	Components of cash and cash equivalents		8501
- On current accounts 434.58 408.11 - In deposit accounts (with original maturity of 3 months or less) - 596.2		19.48	35.91
- In deposit accounts (with original maturity of 3 months or less)			ine to
		434.58	10.000000000000000000000000000000000000
	- In deposit accounts (with original maturity of 3 months or less) Total	454.06	1,040.26



